Euphoric Performance for Psychedelics ETF in 2025

Watch Euphoric Performance for Psychedelics ETF in 2025 - Bloomberg on Dailymotion

Transcript

00:00Let's talk about performance because like Eric mentioned, three straight years of double digit

00:05declines. Then you take a look at year to date performance in 2025. This ETF is higher by about

00:1162 percent on a total return basis. What changed in 2025? An awful lot changed. A big one was

00:20getting RFK into the head of the HHS. And then you just have to look at an awful lot of public

00:29perception, acceptance for alternative health care treatments, getting more and more acceptance

00:37worldwide. And also, you know, these psychedelic treatments, alternative health care treatments

00:46for traumatic brain injury, untreatable depression, PTSD, all sorts of things have been moving through

00:53their FDA trials. And these very new micro cap companies that a few years ago weren't getting

01:03much play at all in the public perception and among investors now are moving into, you know,

01:14series three trials, series two trials, FDA and moving quite along. So after getting beat up badly

01:23for for three years or so in the past year, they're really getting some play. And when you look at their

01:31prices, I still think they have a great deal of upside, even though we've had a nice year to date

01:38so far. So like biotech stocks, many of them are probably unprofitable because they are building out

01:44their pipeline and building out what they can offer. And you talk about this progress on clinical trials.

01:50Are these candidates for being acquisition targets for big pharma or at least somewhat bigger

01:56pharmaceutical companies, given that those companies need to refill their pipeline of drugs?

02:01Certainly, certainly. And we've seen a few acquisitions among these companies, big pharma

02:07buying up these micro cap psychedelic specialty companies. Now, I think we all know those things

02:13are impossible to bet on, impossible to pick the winners of. But that's an important thing about

02:21having an ETF with all these companies making up the portfolio. It's really nice when one of them

02:29gets acquired for a nice premium buyout price. And Dan, Eric here, just in about 40 seconds,

02:36what is the total market for this? And how much of that market is cannabis versus those other drugs?

02:43Well, nothing to do with cannabis here. And that's what we always have to completely explain

02:48and and set apart. A lot of cannabis stocks are based on one, you have medical cannabis to you have

02:55states that have adult use. There's nothing like that in psychedelics. You know, a few areas have

03:01decriminalized things like that. But these are real NYSE and NASDAQ listed biotech companies doing legal

03:10business, FDA trials of real treatments and real drugs. They just happen to be using psilocybin and

03:18ketamine, MDMA and others. I think there's a huge market for it. And this is still just in its infancy.